Premium
Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications
Author(s) -
SCHELLENS JAN H.M.,
MALIEPAARD MARC,
SCHEPER RIK J.,
SCHEFFER GEORGE L.,
JONKER JOHAN W.,
SMIT JOHAN W.,
BEIJNEN JOS H.,
SCHINKEL ALFRED H.
Publication year - 2000
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2000.tb07037.x
Subject(s) - abcg2 , mitoxantrone , topotecan , cancer research , atp binding cassette transporter , pharmacology , multiple drug resistance , p glycoprotein , ovarian cancer , cancer , cancer cell , efflux , medicine , drug resistance , chemistry , biology , transporter , chemotherapy , biochemistry , microbiology and biotechnology , gene
A bstract : The multidrug resistance protein BCRP (breast cancer resistance protein) is a member of the ATP‐binding cassette family of drug transporters. Overexpression of BCRP caused by exposure of cells to mitoxantrone (MX) or doxorubicin/verapamil resulted in a resistance pattern that is different from what is generally seen in the case of P‐glycoprotein and MRP1 overexpression. Recently, the BCRP gene has been described in ovarian, breast, colon,and gastric cancer and fibrosarcoma cell lines. Our human tumor cells T8 and MX3, derived from the ovarian cancer cell line IGROV1 by stepwise increased exposure to topotecan and MX, are resistant to topotecan, CPT11, SN38, and 9‐aminocamptothecin as well as MX. Increased energy‐dependent efflux of affected drugs was noted. BCRP is a very efficient transporter of topotecan. Our recent studies, using the monoclonal antibody (mAb) BXP34, revealed that BCRP is located in the plasma membrane of the T8 and MX3 cell lines. Preliminary results of staining of human tumor cells showed low or absent levels of BCRP in a panel of solid tumors and acute myeloid leukemia cells.